Sarah Jordan

Sarah Jordan

Partner
Sarah Jordan
London
+44 (0)20 4536 3114

Sarah Jordan is a partner in Goodwin’s Antitrust and Competition practice. Dual qualified to practice in both England & Wales and Belgium, Sarah has a broad range of experience advising on European and UK competition law matters, including EU, UK and international merger control and foreign investment matters, antitrust counselling, cartels and compliance.

Sarah is recognized as a leading lawyer in The Legal 500 UK and Who’s Who Legal Global Elite.

Experience

Sarah’s experience includes work with sectors as diverse as pharmaceuticals, air transport, directory and internet services, basic manufacturing and construction materials, chemicals, brewing, digital storage products, financial services, and paper. Her representative experience includes advising: 

  • TowerBrook Capital Partners on the establishment of a new real estate lending platform, Precede Capital Partners (formerly Précis), with a multi-billion pound residential development fund and the subsequent stake sale to and joint venture partnership with QuadReal Property Group
  • Saale-Krankenhaus Calbe GmbH, the German subsidiary of the Medicover Group (LSE: 0RPS, Stockholm Stock Exchange: MCOVBS)(“Medicover”), in its acquisition of 80 percent shares in DDent MVZ GmbH (“DDent”) from the sole shareholder and CEO Dr. Nicol Dudek based on an enterprise evaluation of approximately EUR 20,000,000
  • Advising UK-based RSV company ReViral in its agreement to be acquired by Pfizer, Inc. for up to $525 million (pending)
  • Biocon Biologics Ltd. in its $3.335 billion (cash up to $2.335 billion plus stock in BBL valued at $1 billion) agreement to acquire Viatris Inc.’s global biosimilars business (pending)
  • Citrix Systems in its definitive agreement under which affiliates of Vista Equity Partners, and Evergreen Coast Capital Corporation, an affiliate of Elliott Investment Management L.P., will acquire Citrix for $16.5 billion (pending)
  • Mimecast Limited in its definitive agreement to be acquired by Permira for approximately $5.8 billion (pending)
  • InPost S.A. on the acquisition of Mondial Relay, a French e-commerce out-of-home parcel delivery platform*
  • GTCR and Corza Health, Inc., on the acquisition of TachoSil® Fibrin Sealant Patch from Takeda Pharmaceutical Company Limited*
  • A bidding consortium led by Advent, Cinven and the RAG-Stiftung on the acquisition of the elevator division of thyssenkrupp AG*
  • Accelya, a portfolio company of Vista Equity Partners, on the acquisition of Farelogix Inc*
  • Avaya Holdings Corp. on a strategic partnership with RingCentral, Inc*
  • Advanced, a portfolio company of BC Partners and Vista Equity Partners, on its acquisition of legal technology business Tikit Limited from BT*
  • Bain Capital on its acquisition of DSM Sinochem Pharmaceuticals*
  • Valeo Foods, a portfolio company of CapVest, on its acquisition of Tangerine Confectionery, the leading supplier of private label sugar confectionery in the UK*
  • Accuride Corporation, a portfolio company of Crestview Partners, in connection with the acquisition of mefro wheels*
  • Creat Group Corporation on its acquisition of Biotest AG*
  • Bain Capital and Cinven on their joint public takeover offer for the German pharmaceutical company Stada Arzneimittel AG*
  • Bain Capital on its $3.2 billion acquisition of Diversey (the food hygiene and cleaning division of Sealed Air Corporation)*
  • Vista Equity Partners in its $1.6 billion take-private acquisition of Infoblox Inc*
  • Bain Capital Private Equity and Vista Equity Partners on the $2.7 billion acquisition of Vertafore*
  • Vista Equity Partners on the $1.65 billion acquisition of Cvent, Inc*
  • Montagu Private Equity on its sale of CliniSys to Roper Technologies*
  • Bain Capital and Advent International on the DKK17 billion acquisition of Nordic card-payment company Nets Holding AS*
  • Tomkins Plc before the European Commission, and in connection with annulment proceedings before the European General Court and Court of Justice in Luxembourg*
  • Lafarge before the European and UK competition authorities on the creation of a joint venture comprising Lafarge and Anglo American (Tarmac)’s UK construction materials businesses*
  • United Airlines on its merger with Continental*
  • Schering-Plough on its US$41 billion merger with Merck*
  • The Greek government on the State aid aspects of the restructuring and privatization of Olympic Airlines and Olympic Airways Services*
  • Schering-Plough on its acquisition of Organon BioSciences*

*Denotes experience prior to joining Goodwin.

Professional Experience

Prior to joining Goodwin, Sarah was most recently a partner at Kirkland & Ellis International LLP in London.

Professional Activities

Sarah is a committee member and past chair of The Competition Section, Law Society of England and Wales. She is also a member of the American Bar Association, Antitrust Section.

Credentials

Education

Post-Graduate DiplomaEconomics for Competition Law2008

King’s College London

Legal Practice Course1999

The University of Law, Guildford

LLB1998

University of Bristol, Bristol, UK

European Legal Studies1997

University of Freiburg

Admissions

Bars

  • England & Wales
  • Brussels Bar (A List)

Recognition & Awards

Sarah is recognized for her work in The Legal 500 UK 2021 as a Leading Individual in EU and Competition law. She is also recognized in ‘Competition - Global Elite Thought Leader’ (2022) by Who’s Who Legal and describes her as “excellent at quickly identifying key issues in merger control and antitrust matters”.

Sarah was identified as a ‘Rising Star’ (2014) by Law360.

Publications

Sarah's publications include:

  • Co-Author, “EU Antitrust vs. U.S. Companies,” Law360, February 4, 2016

Her speaking engagements include:

  • Speaker, "Antitrust: Implications for M&A and JVs," GCR Live 6th Annual Antitrust Law Leaders Forum, Miami, February 2017
  • Speaker, "Compliance Workshop," IBC Legal, Advanced EU Competition Law Conference, Brussels, November 2016